scholarly journals 49. Schnitzler syndrome: a case of chronic urticaria and monoclonal gammopathy

2018 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Catherine M McGrath ◽  
Karen M J Douglas
Author(s):  
Elisabeth Eiling ◽  
Johann O. Schröder ◽  
Wolfgang L. Gross ◽  
Inga Kreiselmaier ◽  
Ulrich Mrowietz ◽  
...  

2008 ◽  
Vol 56 (6) ◽  
pp. 1152-1153 ◽  
Author(s):  
Antoine Elsendoorn ◽  
Julien Voultoury ◽  
Anne-Sophie Gaubert ◽  
Antoine Elsendoorn ◽  
Julien Voultoury ◽  
...  

2018 ◽  
Vol 24 (1) ◽  
Author(s):  
Kelly Wilmas ◽  
Alexander Aria ◽  
Carlos A Torres-Cabala ◽  
Huifang Lu ◽  
Madeleine Duvic

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Yuya Fujita ◽  
Tomoyuki Asano ◽  
Akira Sakai ◽  
Natsumi Norikawa ◽  
Toshiyuki Yamamoto ◽  
...  

Abstract Background Schnitzler’s syndrome (SchS) is a rare autoinflammatory syndrome with diagnostic challenge and be characterized by chronic urticaria, a monoclonal gammopath, periodic fever and bone pain. In addition to the monoclonal gammopathy, bone abnormalities are often found at the site of bone pain in patients with SchS. The remarkable efficacy of interleukin-1 (IL-1) inhibition was also demonstrated in this syndrome. Case presentation We describe a case of refractory chronic urticaria presenting with clinical manifestations consistent with SchS without monoclonal gammopathy. A 43-year-old female patient suffering from recurring of urticaria with periodic fever as well as bone pain for the past 4 years. The patient had leukocytosis and elevated levels of C-reactive protein (CRP) and serum amyloid A (SAA). PET/CT (positron emission tomography/computed tomography) and MRI (magnetic resonance imaging) examination revealed hyper-metabolism areas in both femoral bone marrow. Although bone marrow histology revealed no abnormality, urticarial skin lesions shows neutrophilic infiltrations without evidence of vasculitis. We could not exclude the possibility of SchS. The patient had been treated with antihistamines, steroids, omarizumab, colchicine and cyclosporine A, no therapeutic effect was observed. She was started on canakinumab 150 mg subcutaneous injection with 4 weeks interval. Within 48 h after the first injection, the urticarial rash disappeared, and febrile attack and bone pain had not recurred. Elevated levels of serum CRP and SAA were normalized within a week after the first injection of canakinumab. Conclusions The current case suggests an important role for IL-1 as a mediator in the pathophysiology of SchS-like refractory urticaria with bine pain. It had been presumed that monoclonal gammopathy may not always present in SchS. It is important to avoid delay in diagnosis and initiation of proper treatment in SchS or autoinflammatory conditions resembling SchS.


2019 ◽  
pp. 34-37
Author(s):  
Pablo Finucci Curi

Schnitzler syndrome is a rare disorder characterized by chronic urticarial rash and monoclonal gammopathy, accompanied by intermittent fever, arthralgia or arthritis, bone pain and lymphadenopathy, in which interleukin 1 (IL-1) has a preponderant role. The case of a 48-year-old male who meets criteria for Schnitzler syndrome and who after failing too many treatments presents a successful response to canakinumab is presented here.


2018 ◽  
Vol 59 (1) ◽  
pp. 154 ◽  
Author(s):  
Min Joo Ahn ◽  
Ji Eun Yu ◽  
Jiung Jeong ◽  
Da Woon Sim ◽  
Young-Il Koh

2018 ◽  
Vol 4 (4) ◽  
pp. 386-389
Author(s):  
Hélène Fank ◽  
Jo Caers ◽  
Michel Lambert ◽  
Liliane Marot ◽  
Laurence De Montjoye ◽  
...  

2012 ◽  
Vol 109 (2) ◽  
pp. 147-148 ◽  
Author(s):  
Sima Patel ◽  
Sayantani Sindher ◽  
Sunit Jariwala ◽  
Golda Hudes

2021 ◽  
Vol 10 (3) ◽  
pp. 143-146
Author(s):  
Jyothika Mamadgi ◽  
Laila Babar ◽  
Rama Bhagavatula ◽  
Santhosh Sadashiv ◽  
Kossivi Dantey ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document